Search

Your search keyword '"Marielle Perry"' showing total 7 results
Start Over Author "Marielle Perry"
7 results on '"Marielle Perry"'

1. Type I IFN immunoprofiling in COVID-19 patients

Author

Rémi Pescarmona, Anne Conrad, Bruno Lina, Martine Valette, Sylvie Pons, Vanessa Escuret, Tristan Ferry, Christelle Compagnon, Geneviève Billaud, Maude Bouscambert, Florent Valour, Christine Lombard, William Mouton, Pierre Lecam, Sandrine Roux, Fabienne Venet, Patrick Miailhes, Valérie Cheynet, Claire Triffault-Fillit, Sophie Trouillet-Assant, Pierre Chauvelot, Marine Villard, Clément Munier, Louis Chauvelot, Sébastien Viel, Guillaume David, Emilie Frobert, Agathe Becker, Laure Folliet, Lorna Garnier, Laurent Bitker, Paul Chabert, Florence Ader, Alexandre Gaymard, Jean-Christophe Richard, Grégory Destras, Laurence Josset, Magali Perret, Antonin Bal, Karen Brengel-Pesce, Guy Oriol, Thomas Perpoint, Laurence Generenaz, Cécile Pouderoux, Florence Morfin, Marielle Perry, Mehdi Mezidi, Christian Chidiac, Yonis Hodane, Judith Provoost, Nicholas Benech, Alexandre Belot, Thierry Walzer, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), BIOMERIEUX, Centre de référence des rhumatismes inflammatoires et maladies autoimmunes systémiques rares de l'enfant [Hôpital Femme Mère Enfant, HCL] (RAISE), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), COVID HCL Study group: William Mouton, Guy Oriol, Christelle Compagnon, Laurence Generenaz, Valérie Cheynet, Florence Ader, Agathe Becker, Nicholas Benech, Pierre Chauvelot, Christian Chidiac, Anne Conrad, Tristan Ferry, Patrick Miailhes, Thomas Perpoint, Marielle Perry, Cécile Pouderoux, Sandrine Roux, Claire Triffault-Fillit, Florent Valour, Yonis Hodane, Louis Chauvelot, Paul Chabert, Judith Provoost, Guillaume David, Laure Folliet, Pierre Lecam, Geneviève Billaud, Maude Bouscambert, Vanessa Escuret, Emilie Frobert, Antonin Bal, Grégory Destras, Laurence Josset, Florence Morfin, Clément Munier, Martine Valette, Fabienne Venet, Lorna Garnier, Rémi Pescarmona, Christine Lombard, Thierry Walzer, ANR-20-COVI-0025,iCovid,Immunopathologie du COVID-19 à l'Assistance Publique Hôpitaux de Paris(2020), Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and CCSD, Accord Elsevier

Subjects
Adult, Male, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Pneumonia, Viral, Immunology, 03 medical and health sciences, Betacoronavirus, 0302 clinical medicine, Pandemic, Medicine, Humans, Immunology and Allergy, Viral immunology, Pandemics, 030304 developmental biology, Aged, Aged, 80 and over, 0303 health sciences, biology, business.industry, SARS-CoV-2, COVID-19, Middle Aged, medicine.disease, biology.organism_classification, Virology, [SDV] Life Sciences [q-bio], Pneumonia, 030220 oncology & carcinogenesis, Interferon Type I, Female, business, Coronavirus Infections
Abstract

International audience; No abstract available

Published
2020
Full Text
View/download PDF

2. Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays

Author

Jérôme, Adnot, Dulce, Alfaiate, Antonin, Bal, Alain, Bergeret, André, Boibieux, Florent, Bonnet, Gaëlle, Bourgeois, Florence, Brunel-Dalmas, Eurydice, Caire, Barbara, Charbotel, Pierre, Chiarello, Laurent, Cotte, d'Aubarede, Constance, François, Durupt, Vanessa, Escuret, Pascal, Fascia, Jean-Baptiste, Fassier, Juliette, Fontaine, Lucie, Gaillot-Durand, Alexandre, Gaymard, Myriam, Gillet, Matthieu, Godinot, François, Gueyffier, Nicolas, Guibert, Laurence, Josset, Matthieu, Lahousse, Bruno, Lina, Hélène, Lozano, Djamila, Makhloufi, Amélie, Massardier-Pilonchéry, Marie-Paule, Milon, Frédéric, Moll, Florence, Morfin, David, Narbey, Julie-Anne, Nazare, Fatima, Oria, Adèle, Paul, Marielle, Perry, Virginie, Pitiot, Mélanie, Prudent, Muriel, Rabilloud, Audrey, Samperiz, Isabelle, Schlienger, Chantal, Simon, Mary-Anne, Trabaud, Sophie, Trouillet-Assant, Martine, Valette, Bal, Antonin, Trabaud, Mary-Anne, Fassier, Jean-Baptiste, Rabilloud, Muriel, Saker, Kahina, Langlois-Jacques, Carole, Guibert, Nicolas, Paul, Adèle, Alfaiate, Dulce, Massardier-Pilonchery, Amélie, Pitiot, Virginie, Morfin-Sherpa, Florence, Lina, Bruno, Pozzetto, Bruno, and Trouillet-Assant, Sophie

Published
2021
Full Text
View/download PDF

3. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia

Author

Sandrine Hayette, Marielle Perry, Xavier Thomas, Clément Rocher, Christian Recher, Etienne Paubelle, Fiorenza Barraco, Hélène Labussière-Wallet, Sarah Bertoli, Sophie Ducastelle, and Gilles Salles

Subjects
Male, Oncology, Cancer Research, medicine.medical_treatment, Kaplan-Meier Estimate, Blast Count, medicine.disease_cause, fluids and secretions, 0302 clinical medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Mutation, Hematopoietic Stem Cell Transplantation, Nuclear Proteins, Myeloid leukemia, hemic and immune systems, Hematology, Middle Aged, Prognosis, Combined Modality Therapy, Leukemia, Myeloid, Acute, Treatment Outcome, medicine.anatomical_structure, Tandem Repeat Sequences, 030220 oncology & carcinogenesis, Cytogenetic Analysis, embryonic structures, Female, Nucleophosmin, Tyrosine kinase, Adult, medicine.medical_specialty, NPM1, Young Adult, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Protein Interaction Domains and Motifs, Aged, Retrospective Studies, Chemotherapy, business.industry, Retrospective cohort study, fms-Like Tyrosine Kinase 3, Bone marrow, business, 030215 immunology
Abstract

Background Outcome of patients with mutation of the FLT3 tyrosine kinase domain (FLT3-TKD) in acute myeloid leukemia (AML) remains controversial. Patients and Methods Herein, we present a retrospective study of 126 newly diagnosed patients with AML performed in 2 French centers. Results FLT3-TKD mutations represented 12.7% of patients, whereas FLT3-internal tandem duplication (ITD) mutation was observed in 20.6% of AML cases and 1.6% of patients harbored both anomalies. At diagnosis, FLT3-TKD and FLT3-ITD were associated with higher peripheral leukocytes count and a higher blast count in bone marrow (P Conclusion Our data suggest that FLT3-TKD mutations should be routinely determined at the time of diagnosis. In association with NPM1 mutations, patients should follow the therapeutic schedule of favorable-risk patients with AML.

Published
2018
Full Text
View/download PDF

4. Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays

Author

Bal, Antonin, primary, Trabaud, Mary-Anne, additional, Fassier, Jean-Baptiste, additional, Rabilloud, Muriel, additional, Saker, Kahina, additional, Langlois-Jacques, Carole, additional, Guibert, Nicolas, additional, Paul, Adèle, additional, Alfaiate, Dulce, additional, Massardier-Pilonchery, Amélie, additional, Pitiot, Virginie, additional, Morfin-Sherpa, Florence, additional, Lina, Bruno, additional, Pozzetto, Bruno, additional, Trouillet-Assant, Sophie, additional, Jérôme, Adnot, additional, Dulce, Alfaiate, additional, Antonin, Bal, additional, Alain, Bergeret, additional, André, Boibieux, additional, Florent, Bonnet, additional, Gaëlle, Bourgeois, additional, Florence, Brunel-Dalmas, additional, Eurydice, Caire, additional, Barbara, Charbotel, additional, Pierre, Chiarello, additional, Laurent, Cotte, additional, d'Aubarede, Constance, additional, François, Durupt, additional, Vanessa, Escuret, additional, Pascal, Fascia, additional, Jean-Baptiste, Fassier, additional, Juliette, Fontaine, additional, Lucie, Gaillot-Durand, additional, Alexandre, Gaymard, additional, Myriam, Gillet, additional, Matthieu, Godinot, additional, François, Gueyffier, additional, Nicolas, Guibert, additional, Laurence, Josset, additional, Matthieu, Lahousse, additional, Bruno, Lina, additional, Hélène, Lozano, additional, Djamila, Makhloufi, additional, Amélie, Massardier-Pilonchéry, additional, Marie-Paule, Milon, additional, Frédéric, Moll, additional, Florence, Morfin, additional, David, Narbey, additional, Julie-Anne, Nazare, additional, Fatima, Oria, additional, Adèle, Paul, additional, Marielle, Perry, additional, Virginie, Pitiot, additional, Mélanie, Prudent, additional, Muriel, Rabilloud, additional, Audrey, Samperiz, additional, Isabelle, Schlienger, additional, Chantal, Simon, additional, Mary-Anne, Trabaud, additional, Sophie, Trouillet-Assant, additional, and Martine, Valette, additional

Published
2021
Full Text
View/download PDF

5. Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Author

Marie-Elodie Langlois, Christian Chidiac, Hélène Labussière-Wallet, Florence Ader, Gilles Salles, Florent Valour, Fiorenza Barraco, Anne Conrad, Chantal Roure-Sobas, Tristan Ferry, Marie Balsat, Marielle Perry, Mathilde Boccard, Marie-Virginie Larcher, Sophie Ducastelle-Lepretre, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Institut des Agents Infectieux [Lyon] (IAI), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), CCSD, Accord Elsevier, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, medicine.medical_specialty, Hepatitis B virus, Hepatitis B vaccine, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Immunization, Secondary, Hematopoietic stem cell transplantation, Booster dose, medicine.disease_cause, complex mixtures, Gastroenterology, Cohort Studies, 03 medical and health sciences, Hepatitis B virus vaccine, 0302 clinical medicine, Internal medicine, medicine, Humans, Prospective Studies, Vaccines, Combined, Child, Diphtheria-Tetanus-Pertussis Vaccine, Immunization Schedule, 030304 developmental biology, Haemophilus Vaccines, 0303 health sciences, Transplantation, Tetanus, business.industry, Diphtheria, Vaccination, Haemophilus influenzae type b, Hematopoietic Stem Cell Transplantation, Infant, Hematology, Hepatitis B, medicine.disease, Antibodies, Bacterial, 3. Good health, [SDV] Life Sciences [q-bio], Poliovirus Vaccine, Inactivated, 030220 oncology & carcinogenesis, business
Abstract

International audience; Data on immunogenicity and safety of the recommended revaccination schedule against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b (Hib), and hepatitis B in adult allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients are limited. This prospective single-center cohort study (April 2014 to March 2018) included adult allo-HSCT recipients referred to a dedicated vaccinology consultation and vaccinated with the pediatric combined diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliovirus, and Haemophilus influenzae type b (DTaP(±HB)-IPV-Hib) vaccine (3 doses 1 month apart, booster dose 1 year later). The proportion of responders to tetanus, diphtheria, Hib, and hepatitis B vaccine and geometric mean concentrations (GMCs) of antibodies were assessed before and up to 24 months after vaccination. A total of 106 patients were vaccinated at a median (interquartile range) time of 12.4 (10 to 18.4) months post-transplant. At 5.3 (4.8 to 6.6) and 23.1 (21.1 to 25.1) months after vaccine initiation, high and sustained rates of protective antibody titers were achieved for tetanus (97.8% [95% confidence interval (95% CI), 92.4% to 99.7%], n = 91/93 and 100% [95% CI, 92% to 100%], n = 44/44), diphtheria (94.6% [95% CI, 87.9% to 98.2%], n = 88/93 and 90.9% [95% CI, 78.3% to 97.5%], n = 40/44), Hib (96.6% [95% CI, 90.4% to 99.3%], n = 85/88 and 93% [95% CI, 80.9% to 98.5%], n = 40/43), and hepatitis B (83.5% [95% CI, 73.5% to 90.9%], n = 66/79 and 81.1% [95% CI, 64.8% to 92%], n = 30/37). Underlying disease, stem cell source, chronic graft-versus-host-disease, and extracorporeal photopheresis differentially influenced GMCs of tetanus, diphtheria, and hepatitis B antibodies after 3 doses but not in the long term (24 months). Six (5.7%) patients experienced mild side effects. The pediatric DTaP(±HB)-IPV-Hib vaccine was safe and effective in eliciting a sustained protective humoral response in adult allo-HSCT recipients. Hepatitis B revaccination might be optimized by using higher antigen doses.

Published
2020
Full Text
View/download PDF

6. Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas

Author

Suzanne Tavitian, Camille Laurent, David Ribes, Marielle Perry, Céline Guilbeau-Frugier, Lucie Oberic, Hélène El Hachem, Anne-Sophie Michallet, François Vergez, Antoine Huart, Dominique Chauveau, Loic Ysebaert, Stanislas Faguer, and Antoine Delarche

Subjects
medicine.medical_specialty, Pathology, Cyclophosphamide, business.industry, Renal function, Hematology, medicine.disease, Gastroenterology, Lymphoma, Membranous nephropathy, Glomerulopathy, Internal medicine, Monoclonal, Membranoproliferative glomerulonephritis, medicine, Rituximab, business, medicine.drug
Abstract

Indolent non-hodgkin lymphomas (iNHL) are a rare cause of monoclonal immunoglobulin deposits-related glomerulopathy (mIgGN). In patients with iNHL-related mIgGN, whether treatment should include either single or a combination of drug(s) to target the malignant clone and renal inflammation remains elusive. In this retrospective study, we report a cohort of 14 patients with iNHL-related mIgGN (cryoglobulinemic glomerulonephritis [n = 5], membranous nephropathy [n = 3], membranoproliferative glomerulonephritis [n = 3], AL or AL/AH amyloidosis [n = 2], and Light Chain Deposits Disease [n = 1]) and who received a treatment combining rituximab, cyclophosphamide, and dexamethasone (RCD). After a mean follow-up of 18 ± 4 months, nine patients (63%) had complete haematological response. Renal response was observed in 12 of the 14 patients (86%; complete response: n = 9; partial: n = 3). Estimated glomerular filtration rate increased from 47 ± 7 to 63 ± 8 mL/min/1.73 m(2) , and proteinuria decreased from 6.5 ± 0.7 to 1.4 ± 0.8 g/24 hr at one year. Following hematological relapse, renal relapse occurred in two patients suggesting sustained clonal eradication offers the best renal protection. Tolerance of RCD was good and the most frequent adverse event was pneumonia (3/14, 21%). RCD is a promising regimen for patients with iNHL and mIgGN, irrespective of glomerular pathologic pattern. Whether steroids can be avoided or minimized remains to be addressed.

Published
2014
Full Text
View/download PDF

7. Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas

Author

Marielle, Perry, Antoine, Delarche, David, Ribes, François, Vergez, Céline, Guilbeau-Frugier, Camille, Laurent, Antoine, Huart, Suzanne, Tavitian, Hélène, El Hachem, Lucie, Oberic, Dominique, Chauveau, Anne-Sophie, Michallet, Loïc, Ysebaert, and Stanislas, Faguer

Subjects
Aged, 80 and over, Male, Glomerulonephritis, Membranoproliferative, Lymphoma, Non-Hodgkin, Plaque, Amyloid, Pneumonia, Middle Aged, Dexamethasone, Antibodies, Monoclonal, Murine-Derived, Proteinuria, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Rituximab, Cyclophosphamide, Aged, Follow-Up Studies, Glomerular Filtration Rate
Abstract

Indolent non-hodgkin lymphomas (iNHL) are a rare cause of monoclonal immunoglobulin deposits-related glomerulopathy (mIgGN). In patients with iNHL-related mIgGN, whether treatment should include either single or a combination of drug(s) to target the malignant clone and renal inflammation remains elusive. In this retrospective study, we report a cohort of 14 patients with iNHL-related mIgGN (cryoglobulinemic glomerulonephritis [n = 5], membranous nephropathy [n = 3], membranoproliferative glomerulonephritis [n = 3], AL or AL/AH amyloidosis [n = 2], and Light Chain Deposits Disease [n = 1]) and who received a treatment combining rituximab, cyclophosphamide, and dexamethasone (RCD). After a mean follow-up of 18 ± 4 months, nine patients (63%) had complete haematological response. Renal response was observed in 12 of the 14 patients (86%; complete response: n = 9; partial: n = 3). Estimated glomerular filtration rate increased from 47 ± 7 to 63 ± 8 mL/min/1.73 m(2) , and proteinuria decreased from 6.5 ± 0.7 to 1.4 ± 0.8 g/24 hr at one year. Following hematological relapse, renal relapse occurred in two patients suggesting sustained clonal eradication offers the best renal protection. Tolerance of RCD was good and the most frequent adverse event was pneumonia (3/14, 21%). RCD is a promising regimen for patients with iNHL and mIgGN, irrespective of glomerular pathologic pattern. Whether steroids can be avoided or minimized remains to be addressed.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results